We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Editorial: Drug-Induced Liver Injury in Clinical Trials: As Rare as Hens’ Teeth.
- Authors
Davern, Timothy J.; Chalasani, Naga
- Abstract
Severe drug-induced liver injury is a relatively rare but important public health problem. Extrapolating the incidence of this problem from clinical treatment trials is confounded by a number of issues, including the relatively small size of clinical trials, exclusion criteria for study participation, and active surveillance for liver injury. Advances in understanding the pathogenesis of drug-induced liver injury, as well as its prevention and treatment, will likely require the identification and careful characterization of severe cases in the post-marketing, “real-world“ setting as part of a concerted, multi-center, well-orchestrated effort. The Drug-Induced Liver Injury Network (DILIN) represents one example of such an effort.Am J Gastroenterol 2009; 104:1159–1161; doi:10.1038/ajg.2009.76; published online 7 April 2009
- Subjects
CLINICAL trials; PUBLIC health; EXTRAPOLATION; LIVER diseases
- Publication
American Journal of Gastroenterology (Springer Nature), 2009, Vol 104, Issue 5, p1159
- ISSN
0002-9270
- Publication type
Article
- DOI
10.1038/ajg.2009.76